Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON40283
NL-OMON40283
Completed
Not Applicable

Aldosterone-induced microvascular dysfunction as a cause of salt-sensitivity in obesity? - Aldosterone, microvascular function and salt-sensitivity

Medisch Universitair Ziekenhuis Maastricht0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsinsulin resistance/decreased sensitivity for insulinsalt-sensitivity of blood pressure1001842410057166

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
insulin resistance/decreased sensitivity for insulin
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
40
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • •Obese individuals
  • •\- Age 18\-65 years
  • •\- Caucasian (because of ethnic differences in microvascular function and in the prevalence of cardiovascular disease and associated risk factors)
  • •\- Waist circumference \> 102 cm (men)/\> 88 cm (women) ;Lean individuals
  • •\- Age 18\-65 years
  • •\- Caucasian (because of ethnic differences in microvascular function and in the prevalence of cardiovascular disease and associated risk factors)
  • •\- Waist circumference \< 94 cm (men)/\< 80 cm (women)

Exclusion Criteria

  • •\- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
  • •\- Diabetes mellitus/impaired glucose metabolism (fasting glucose values \> 6\.1 mmol/L), because not only diabetes, but also intermediate hyperglycaemia has been associated with microvascular disease, which impedes the distinction between cause and consequence of disturbances in glucose metabolism in the concerning individuals
  • •\- Stage 3 hypertension (blood pressure \> 180/110 mm Hg) in order not to expose these persons to unnecessary risks
  • •\- Unstable or severe pulmonary disease
  • •\- Unstable or severe thyroid disorders
  • •\- Inflammatory diseases
  • •\- Smoking (due to impairment of microvascular function)
  • •\- Alcohol use \> 2 U/day (women)/\> 3 U/day (men)
  • •\- Use of glucose\-lowering medications, because of interference with microvascular function
  • •\- Use of corticosteroids (might cause hypertension and interfere with electrolyte homeostasis and glucose metabolism) and regular use (weekly or several times a week) of NSAIDs (might cause disturbance of microvascular function and electrolyte excretion)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Effects of aldosterone antagonism on microvascular function in obese individuals
NL-OMON45212niversiteit Maastricht60
Completed
Not Applicable
The role of aldosterone in cardiovascular disease in chronic renal failure
ISRCTN37814228Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)200
Not yet recruiting
Not Applicable
Clinical significance of plasma aldosterone concentration in patients with primary aldosteronismPrimary aldosteronism
JPRN-UMIN000016201Department of Metabolic Medicine, Osaka University Graduate School of Medicine750
Recruiting
Not Applicable
Primary hyperaldosteronism and endothelial ischemia-reperfusion injuryprimary aldosteronismprimary hyperaldosteronism1001108210057166
NL-OMON38730niversitair Medisch Centrum Sint Radboud40
Completed
Not Applicable
Cardiovascular Evaluation of Adult PHA 1 PatientsPseudohypoaldosteronism Type 1
NCT00646828Assistance Publique - Hôpitaux de Paris98